Reportlinker Adds Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

http://www.reportlinker.com/p0487249/Advanced-Lung-Cancer-with-EGFR-Mutation-Positive-Adenocarcinoma.html

Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

A patient specific case scenario on advanced lung cancer in a situation involving a patient with EGFR Mutation Positive Adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions. Patient progression reveals:

• Decisions in treatment and tests through disease stages

• Factors influencing their decisions

• Barriers to optimal patient care

• Confidence in treatment

Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients

• Access the most up-to-date prescribing trends

• Gain actionable data for developing and improving your market strategies

• Pinpoint needs of your target audience

• Focus resources to maximize the effectiveness of your budget

• Understand where your product fits

• Understand where your competitor's product fits

• Design messages to advance brand performance

Table of Contents

Executive Summary - US Oncologist Survey5

Optimizing Treatment of Advanced Lung Cancer:5

Chapter 1: Introduction6

Table 1: Treatment Options in Advanced Lung Cancer6

Chapter 2: Respondent Demographics8

Table 2: Eligibility Criteria for Survey Participation8

Figure 2.1 Gender of Survey Respondents8

Figure 2.2 Years Since Medical School Graduation9

Figure 2.3 Practice Settings9

Figure 2.4 Practices in NCI Cancer Centers10

Figure 2.5 Geographic Settings10

Figure 2.6 Survey Respondents by State's Lung Cancer Mortality11

Figure 2.7 Number of Physicians in Practice Groups12

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen12

Chapter 3: Treatment of an EGFR Mutation Positive Adenocarcinoma13

Figure 3.1 First line chemotherapy regimen13

Figure 3.2 Factors influencing treatment decision14

Figure 3.3 Confidence in treating patient to an optimal outcome16

Figure 3.4 Sequence of treatment choices17

Figure 3.5 Factors influencing treatment decision18

Figure 3.6 Barriers to management of advanced lung cancer20

Chapter 4: Summary23

Appendix A: Survey Instrument24

Companies mentioned

Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Glaxo Smith Kline, Pfizer, Sanofi-aventis

To order this report:

: Advanced Lung Cancer with EGFR Mutation Positive Adenocarcinoma

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker